Aptorum Group Aktie [WKN DE: A2N6WM / ISIN: KYG6096M1069]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Aptorum Group Ltd Registered Shs -A-

07.03.24		Victoria's Secret, Inovio Pharmaceuticals, Broadcom, Aptorum Group, Tesla: Why These 5 Stocks Are On Investors' Radars Today (Benzinga)
18.05.23		Pre-market Movers: CWD, HOWL, DLO, TTWO, BOOT… (RTTNews)
28.04.23		Pre-market Movers: MEGL, TOP, AGBA, KA, SIEB… (RTTNews)
27.03.23		Aptorum Group Inks Non-binding LoI And Term Sheet To Buy 100% Of URF Holding Group (RTTNews)
27.03.23		Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group (Businesswire)
03.03.23		Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma (Businesswire)
03.03.23		Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus (Businesswire)
02.03.23		Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China (Businesswire)
06.02.23		Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023 (Businesswire)
20.01.23		Aptorum Group Announces 1-for-10 Reverse Stock Split (Businesswire)
22.12.22		Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders (Businesswire)
16.12.22		Aptorum Group Announces Completion of $3 Million Convertible Note due 2023 (Businesswire)
09.12.22		Aptorum Group Announces Offering of $3 Million Convertible Note due 2023 (Businesswire)
18.11.22		Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency (Businesswire)
08.11.22		Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022 (Businesswire)
15.09.22		Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong (Businesswire)
15.09.22		Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics (Businesswire)
26.08.22		Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022 (Businesswire)
17.05.22		Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022 (Businesswire)
02.05.22		Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma (Businesswire)
29.04.22		Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update (Businesswire)
25.04.22		First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted (Businesswire)
22.04.22		Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report® (Businesswire)
28.01.22		Pre-market Movers: IMPP, PRVB, HOOD, ATIF, WDC… (RTTNews)
26.01.22		Pre-market Movers: GATO, XELA, NXPL, XCUR, MYNZ… (RTTNews)
25.01.22		Pre-market Movers: APM, BSFC, INPX, UPC, KAVL… (RTTNews)
24.01.22		Pre-market Movers: BTBD, RETO, KSS, BON, PT… (RTTNews)
21.01.22		Pre-market Movers: BSFC, APM, KTRA, RIOT, PIXY… (RTTNews)
20.01.22		Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma (Businesswire)
18.01.22		Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma (Businesswire)
09.07.21		Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report (Businesswire)
26.05.21		Aptorum Group CEO Subscribed Shares In The Company (Businesswire)
24.05.21		Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma (Businesswire)
13.05.21		Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference (Businesswire)
06.05.21		Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions (Businesswire)
23.04.21		Aptorum Group Limited Interview to Air on Bloomberg Television U.S. on the RedChip Money Report (Businesswire)
22.04.21		Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases (Businesswire)
19.04.21		Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update (Businesswire)
20.01.21		Stock Alert: Aptorum Up 30% On Clearance To Initiate Phase 1 Trial Of ALS-4 In Canada (RTTNews)
07.12.20		Pre-market Movers In Healthcare Sector: OBLN, EYES, CYAD, ONCT, BCRX… (RTTNews)
30.10.20		Pre-market Movers In Healthcare Sector: MGEN, EQ, SNSS, IPHA, BLCM, AXGT… (RTTNews)
29.10.20		Pre-market Movers In Healthcare Sector: VSTM, APM, KALA, BNTX, CGIX... (RTTNews)
16.10.20		Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020 (Businesswire)
02.10.20		Aptorum Group Announces Closing of $9.0 Million Public Offering (Businesswire)
01.10.20		SELB Down But Not Out, PFE Takes 9.9% Stake In CStone, ZSAN Plunges, AMAG On The Block? (RTTNews)
30.09.20		Aptorum Group Announces Pricing of $9.0 Million Public Offering (Businesswire)
08.09.20		Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10 (Businesswire)
08.09.20		Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance (Businesswire)
03.09.20		AGTC Abuzz, AMRN Slumps & CORT Soars As Oral Arguments Commence, FLGT Gears Up, NNVC On Watch (RTTNews)
02.09.20		Aptorum Group Announces Video Update Discussing Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

EQS-Adhoc: STRABAG SE CEO Klemens Haselsteiner passed away completely unexpectedly

Ripple auf dem Weg zu 100 US-Dollar in 2025?

Ripple Kurs Prognose: 10 US-Dollar bis Ende des Jahres?

EQS-Adhoc: STRABAG SE-Vorstandsvorsitzender Klemens Haselsteiner völlig überraschend verstorben

STRABAG-CEO Klemens Haselsteiner verstirbt überraschend

Auric Minerals-Aktie: Kurssturz wegen neuem Vertrag?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	19.01.2025 22:48
Kaufwert:	EUR
	Hinzufügen Speichern